MedTrace Logo

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

NCT02520791 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-04-13

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Stage IV Mycosis Fungoides AJCC v7
  • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
  • Recurrent Grade 1 Follicular Lymphoma
  • Recurrent Grade 2 Follicular Lymphoma
  • Recurrent Grade 3a Follicular Lymphoma
  • Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
  • Recurrent Mycosis Fungoides
  • Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
  • Refractory Grade 1 Follicular Lymphoma
  • Refractory Grade 2 Follicular Lymphoma
  • Refractory Grade 3a Follicular Lymphoma
  • Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
  • Stage IB Mycosis Fungoides AJCC v7
  • Stage II Mycosis Fungoides AJCC v7
  • Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Stage III Mycosis Fungoides AJCC v7
  • Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

Anti-ICOS Monoclonal Antibody MEDI-570

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Julio C Chavez · University Health Network Princess Margaret Cancer Center LAO

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-13
Primary Completion
2024-12-18
Completion
2026-12-24

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02520791 on ClinicalTrials.gov